Analyst Says Acelyrin (SLRN) Dosing Errors Create “Too Much Uncertainty,” Securities Class Action Pending - Hagens Berman
SAN FRANCISCO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 – Sept. 11, 2023 Lead Plaintiff Deadline: Jan. 16, 2024 Visit …